Therapeutic vaccination for cancer

Clinical Immunology

Volumn 95, Issue 1 II, 2000, Pages

  Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT DNA; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; GENETIC TRANSDUCTION; HUMAN; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; VACCINATION;

EID: 0034115922     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4819     Document Type: Conference Paper

References (126)

1. Berd, D., Maguire, H. C. J., and Mastrangelo, M J., Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46, 2572-2577, 1986.
2. Livingston, P. O., Albino, A. P., Chung, T. J., Real, F. X., Houghton, A. N., Oettgen, H. F., and Old, L. J., Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55, 713-720, 1985.
3. Berd, D., Maguire, H. C. J., McCue, P., and Mastrangelo, M. J., Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J. Clin. Oncol. 8, 1858-1867, 1990.
4. McCune, C. S., O'Donnell, R. W., Marquis, D. M., and Sahasrabudhe, D. M., Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32, 62-66, 1990.
5. Thomas, L., "Discussion of Cellular and Humoral Aspects of the Hypersensitive states" (H. S. Lawrence, Ed.), Hoeber-Harper, New York, 1959.
6. Burnet, F. M., The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27, 1970.
7. Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., Malissen, B., Zinkernagel, R. M., and Hengartner, H., Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65, 305-317, 1991.
8. Miller, J. F., Morahan, G., and Allison, J., Extrathymic acquisition of tolerance by T lymphocytes. Cold Spring Harb. Symp. Quant. Biol. 2, 807-813, 1989.
9. Burkly, L. C., Lo, D., Kanagawa, O., Brinster, R. L., and Flavell, R. A., T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class III-E. Nature 342, 564-566, 1989.
10. Staveley-O'Carroll, K. E., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levistky, H., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183, 1998.
11. Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., and Schreiber, H., Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238, 1997.
12. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall, F. K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., and Ohashi, P. S., Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J. Exp. Med. 186, 645-653, 1997.
13. Adler, A. J., Marsh, D. W., Yochum, G. S., Guzzo, J. L., Nigam, A., Nelson, W. G., and Pardoll, D. M., CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187, 1555-1564, 1998.
14. Banchereau, J., and Steinman, R. M., Dendritic cells and the control of immunity. Nature 392, 245-252, 1998.
15. Lindenmann, J., and Klein, P. A., Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126, 93-108, 1967.
16. Fearon, E. R., Itaya, T., Hunt, B., Vogelstein, B., and Frost, P., Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 48, 2975-2980, 1988.
17. Wallich, R., Bulbuc, N., Hammerling, G. J., Katzav, S., Segal, S., and Feldman, M., Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315, 301-305, 1985.
18. Karre, K., Ljunggren, H. G., Piontek, G., and Kiessling, R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319, 675-678, 1986.
19. Itaya, T., Yamagiwa, S., Okada, F., Oikawa, T., Kuzumaki, N., Takeichi, N., Hosokawa, M., and Kobayashi, H., Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). Cancer Res. 47, 3136-3140, 1987.
20. Plautz, G. E., Yang, Z. Y., Wu, B. Y., Gao, X., Huang, L., and Nabel, G. J., Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 90, 4645-4649, 1993.
21. Ostrand-Rosenberg, S., Roby, C., Clements, V. K., and Cole, G. A., Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int. J. Cancer Suppl. 6, 61-68, 1991.
22. Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J., and Glimcher, L. H., Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90, 5687-5690, 1993.
23. Armstrong, T. D., Clements, V. K., and Ostrand-Rosenberg, S., MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J. Immunol. 160, 661-666, 1998.
24. Linsley, P. S., Brady, W., Grosmaire, L., Arffo, A., Damle, N. K., and Ledbetter, J. A., Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730, 1991.
25. Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G., and Thompson, C. B., Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244, 339-343, 1989.
26. Fraser, J. D., Irving, B. A., Crabtree, G. R., and Weiss, A., Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251, 313-316, 1991.
27. Viola, A., Hadjur, C., Jeunet, A., and Julliard, M., Electron paramagnetic resonance evidence of the generation of superoxide (O2 · -) and hydroxyl (· OH) radicals by irradiation of a new photodynamic therapy photosensitizer, Victoria Blue BO. J. Photochem. Photobiol. B 32, 49-58, 1996.
28. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., and Allison, J. P., CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609, 1992.
29. Townsend, S. E., and Allison, J. P., Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells [see comments]. Science 259, 368-370, 1993.
30. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S., Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102, 1992.
31. Sumimoto, H., Tani, K., Nakazaki, Y., Tanabe, T., Hibino, H., Hamada, H., Azuma, M., and Asano, S., GM-CSF and B7-1 (CD80) co-stimulatory signals cooperate in the induction of effective anti-tumor immunity in syngeneic mice. Int. J. Cancer 73, 556-561, 1997.
32. Dummer, R., Yue, F. Y., Pavlovic, J., Geertsen, R., Dohring, C., Moelling, K., and Burg, G., Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: Suppression by interleukin 10. Br. J. Cancer 77, 1413-1419, 1998.
33. Nakazaki, Y., Tani, K., Lin, Z. T., Sumimoto, H., Hibino, H., Tanabe, T., Wu, M. S., Izawa, K., Hase, H., Takahashi, S., Tojo, A., Azuma, M., Hamada, H., Mori, S., and Asano, S., Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Gene Ther. 5, 1355-1362, 1998.
34. Guinn, B. A., DeBenedette, M. A., Watts, T. H., and Berinstein, N. L., 4-1BBL cooperated with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162, 5003-5010, 1999.
35. Wu, T. C., Huang, A. Y. C., Jaffee, E. M., Levitsky, H. I., and Pardoll, D. M., A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182, 1415-1421, 1995.
36. Cayeux, S., Richter, G., Noffz, G., Dorken, B., and Blankenstein, T., Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158, 2834-2841, 1997.
37. Gajewski, T. F., Fallarino, F., Uyttenhove, C., and Boon, T., Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B702 for active tumor immunization. J. Immunol. 156, 2909-2917, 1996.
38. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I., Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769-776, 1996.
39. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., and Hellstrom, K. E., Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532, 1994.
40. Chen, J. J., Sun, Y., and Nabel, G. J., Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717, 1998.
41. Couderc, B., Zitvogel, L., Douin-Echinard, V., Djennane, L., Tahara, H., Favre, G., Lotze, M. T., and Robbins, P. D., Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 5, 163-175, 1998.
42. Kwak, L. W., Young, H. A., Pennington, R. W., and Weeks, S. D., Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93, 10972-10977, 1996.
43. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P., Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403, 1990.
44. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224, 1990.
45. Bubenik, J., Simova, J., and Jandlova, T., Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23, 287-292, 1990.
46. Cavallo, F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Modesti, A., and Forni, G., Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149, 3627-3635, 1992.
47. Bannerji, R., Arroyo, C. D., Cordon, C. C., and Gilboa, E., The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152, 2324-2332, 1994.
48. Rodolfo, M., Zilocchi, C., Melani, C., Cappetti, B., Arioli, I., Parmiani, G., and Colombo, M. P., Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens: Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157, 5536-5542, 1996.
49. D'Angelica, M., Karpoff, H., Halterman, M., Ellis, J., Klimstra, D., Edelstein, D., Brownlee, M., Federoff, H., and Fong, Y., In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol. Immunother. 47, 265-271, 1999.
50. Koppenhagen, F. J., Kupcu, Z., Wallner, G., Crommelin, D. J., Wagner, E., Storm, G., and Kircheis, R., Sustained cytokine delivery for anticancer vaccination: Liposomes as alternative for the gene-transfected tumor cells. Clin. Cancer Res. 4, 1881-1886, 1998.
51. de Vos, S., Kohn, D. B., Cho, S. K., McBride, W. H., Said, J. W., and Koeffler, H. P., Immunotherapy against murine leukemia. Leukemia 12, 401-405, 1998.
52. Sivanandham, M., Shaw, P., Bernik, S. F., Paloetti, E., and Wallack, M. K., Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol. Immunther. 46, 261-267, 1998.
53. Tepper, R. I., Pattengale, P. K., and Leder, P., Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512, 1989.
54. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M., Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716, 1991.
55. Stoppacciaro, A., Paglia, P., Lombardi, L., Parmiani, G., Baroni, C., and Colombo, M. P., Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur. J. Immunol. 27, 2375-2382, 1997.
56. Rodolfo, M., Melani, C., Zilocchi, C., Cappetti, B., Luison, E., Arioli, I., Parenza, M., Canevari, S., and Colombo, M. P., IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 58, 5812-5817, 1998.
57. Gansbacher, B., Bannerji, R., and Daniels, B., Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50, 7820-7826, 1990.
58. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., and Sakata, T., Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86, 9456-9460, 1989.
59. Restifo, N. P., Spiess, P. J., Karp, S. E., Mule, J. J., and Rosenberg, S. A., A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability. J. Exp. Med. 175, 1423-1431, 1992.
60. Asher, M., Mule, J., and Kasid, A., Murine tumor cells transduced with the gene for tumor necrosis factor-1. J. Immunol. 146, 3227-3229, 1991.
61. Karp, S. E., Farber, A., Salo, J. C., Hwu, P., Jaffe, G., Asher, A. L., Shiloni, E., Restifo, N. P., Mule, J. J., and Rosenberg, S. A., Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: Tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol. 150, 896-908, 1993.
62. Blankenstein, T., Qin, Z., and Uberla, K., Tumor suppression after tumor cell-targeted tumor necrosis factor via gene transfer. J. Exp. Med. 173, 1047-1052, 1991.
63. Hock, H., Dorsch, M., Diamantstein, T., and Blankenstein, T., Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174, 1291-1298, 1991.
64. Sharma, S., Miller, P. W., Stolina, M., Zhu, L., Huang, M., Paul, R. W., and Dubinett, S. M., Multicomponent gene therapy vaccines for lung cancer: Effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther. 4, 1361-1370, 1997.
65. Nanni, P., Rossi, I., De Giovanni, C., Landuzzi, L., Nicoletti, G., Stoppacciaro, A., Parenza, M., Colombo, M. P., and Lollini, P. L., Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58, 1225-1230, 1998.
66. Hallez, S., Detremmerie, O., Giannouli, C., Thielemans, K., Gajewski, T. F., Burny, A., and Leo, O., Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int. J. Cancer 81, 428-437, 1999.
67. Popvic, D., El-Shami, K. M., Vadai, E., Feldman, M., Tzehoval, E., and Eisenbach, L., Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12. Clin. Exp. Metast. 16, 623-632, 1998.
68. Toda, M., Martuza, R. L., Kojima, H., and Rabkin, S. D., In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464, 1998.
69. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543, 1993.
70. Hsieh, C. L., Pang, V. F., Chen, D. S., and Hwang, L. H., Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: Implications for cytotoxic T lymphocyte responses and tumor burdens. Hum. Gene Ther. 8, 1843-1854, 1997.
71. McLaughlin, J. P., Abrams, S., Kantor, J., Dobrzanski, M. J., Greenbaum, J., Schlom, J., and Greiner, J. W., Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor induces tumor regression and long-lasting systemic immunity. J. Immunother. 20, 449-459, 1997.
72. Herrlinger, U., Kramm, C. M., Johnston, K. M., Louis, D. N., Finkelstein, D., Reznikoff, G., Dranoff, G., Breakefield, X. O., and Yu, J. S., Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther. 4, 345-352, 1997.
73. Qin, H., and Chatterjee, S. K., Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther. 7, 1853-1860, 1996.
74. Sampson, J. H., Archer, G. E., Ashley, D. M., Fuchs, H. E., Hale, L. P., Dranoff, G., and Bigner, D. D., Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA 93, 10399-10404, 1996.
75. Turner, J. G., Tan, J., Crucian, B. E., Sullivan, D. M., Ballester, O. F., Dalton, W. S., Yang, N. S., Burkholder, J. K., and Yu, H., Broadened clinical utility of gene gun-mediated, granulocyte macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther. 9, 1121-1130, 1998.
76. Qin, Z., Noffz, G., Mohaupt, M., and Blankenstein, T., Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159, 770-776, 1997.
77. Nagai, E., Ogawa, T., Kielian, T., Ikubo, A., and Suzuki, T., Irradiated tumor cells adenovirally engineered to secrete granulocyte macrophage-colony stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunol. Immunother. 47, 72-80, 1998.
78. Hogge, G. S., Burkholdler, J. K., Culp, J., Albertini, M. R., Dubielzig, R. R., Keller, E. T., Yang, N. S., and MacEwen, E. G., Development of human granulocyte macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum. Gene Ther. 9, 1851-1861, 1998.
79. Bonnekoh, B., Greenhalgh, D. A., Chen, S. H., Block, A., Rich, S. S., Krieg, T., Woo, S. L., and Roop, D. R., Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defense in the B16 melanoma model. J. Invest. Dermatol. 110, 867-871, 1998.
80. Dunussi-Joannopoulos, K., Dranoff, G., Weinstein, H. J., Ferrara, J. L., Bierer, B. E., and Croop, J. M., Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 91, 222-230, 1998.
81. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D. M., and Levitsky, H., The central role of CD4+ T cells in the anti-tumor immune response. J. Exp. Med. 188, 2357-2368, 1998.
82. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965, 1994.
83. Thompson, R. C., Pardoll, D. M., Jaffee, E. M., Ewend, M. G., Thomas, M. C., Tyler, B. M., and Brem, H., Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. Emphasis Tumor Immunol. 19, 405-413, 1996.
84. Jaffee, E. M., and Pardoll, D. M., Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 12, 143-153, 1997.
85. Pulaski, B. A., McAdam, A. J., Hutter, E. K., Biggar, S., Lord, E. M., and Frelinger, J. G., Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. 53, 2112-2117, 1993.
86. Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., and Restifo, N. P., Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162, 5728-5737, 1999.
87. Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., and Parmiani, G., Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173, 889-897, 1991.
88. Rollins, B. J., and Sunday, M. E., Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell Biol. 11, 3125-3131, 1991.
89. Porgador, A., Tzehoval, E., Katz, A., Vadai, E., Revel, M., Feldman, M., and Eisenbach, L., Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679-3686, 1992.
90. Dranoff, G., and Mulligan, R. C., Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454, 1995.
91. Dachs, G. U., Dougherty, G. J., Stratford, I. J., and Chaplin, D. J., Targeting gene therapy to cancer: A review. Oncol. Res. 9, 313-325, 1997.
92. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W., Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323, 1997.
93. Roelvink, P. W., Lizonova, A., Lee, J. G., Li, Y., Bergelson, J. M., Finberg, R. W., Brough, D. E., Kovesdi, I., and Wickham, T. J., The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72, 7909-7915, 1998.
94. Li, Y., Pong, R. C., Bergelson, J. M., Hall, M. C., Sagalowsky, A. I., Tseng, C. P., Wang, Z., and Hsieh, J. T., Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330, 1999.
95. Ferrari, F. K., Xiao, X., McCarty, D., and Samulski, R. J., New developments in the generation of Ad-free, high-liter rAAV gene therapy vectors. Nature Med. 3, 1295-1297, 1997.
96. Pincus, S., Tartaglia, J., and Paoletti, E., Poxvirus-based vectors as vaccine candidates. Biologicals 23, 159-164, 1995.
97. Borrello, I., Sotomayor, E. M., Cooke, S., and Levitsky, H. I., A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10, 1983-1991, 1999.
98. Thomas, M. C., Greten, T. F., Pardoll, D. M., and Jaffee, E. M., Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9, 835-843, 1998.
99. Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., and Chen, S. H., Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA 93, 11302-11306, 1996.
100. Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., and Woo, S. L., Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91, 3054-3057, 1994.
101. Nabel, G. J., Nabel, E. G., Yang, Z. Y., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E., Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90, 11307-11311, 1993.
102. Lipshy, K A., Kostuchenko, P. J., Hamad, G. G., Bland, C. E., Barrett, S. K., and Bear, H. D., Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann. Surg. Oncol. 4, 334-341, 1997.
103. Schmidt, W., Schweighoffer, T., Herbst, E., Maass, G., Berger, M., Schilcher, F., Schaffner, G., and Birnstiel, M. L., Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711-4714, 1995.
104. Villanueva, M. S., Fischer, P., Feen, K., and Pamer, E. G., Efficiency of MHC class I antigen processing: A quantitative analysis. Immunity 1, 479-489, 1994.
105. Krummel, M. F., and Allison, J. P., CTLLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533-2540, 1996.
106. Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., and Mak, T. W., Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988, 1995.
107. Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., and Sharpe, A. H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547, 1995.
108. Leach, D. R., Krummel, M. F., and Allison, J. P., Enhancement of antitumor immunity by CLTA-4 blockade. Science 271, 1734-1736, 1996.
109. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., and Allison, J. P., Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94, 8099-8103, 1997.
110. Van Elsas, A., et al., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366, 1999.
111. Hurwitz, A. A., Yu, T. F., Leach, D. R., and Allison, J. P., CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95, 10067-10071, 1998.
112. Hurwitz, A., Choi, E., Fasso, M., and Allison, J. P., Combination vaccination and CTLA-4 blockade for spontaneous murine prostate cancer. Cancer Res., in press, 2000.
113. Kurts, C., Carbone, F. R., Krummel, M. F., Koch, K. M., Miller, J. F. A. P., and Heath, W. R., Signalling through CD30 protects against autoimmune diabetes mediated by CD8 cells. Nature 398, 341-344, 1999.
114. Stingl, G., Brocker, E. B., Mertelsmann, R., Wolff, K., Schreiber, S., Kampgen, E., Schneeberger, A., Trcka, J., Brennscheidt, U., Veelken, H., Birnstiel, M. L., Zatloukal, K., Maass, G., Wagner, E., Buschle, M., Kempe, E. R., Weber, H. A., and Voigt, T., Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. J. Mol. Med. 75, 297-299, 1997.
115. Belli, R., Arienti, F., Sule-Suso, J., Clemente, C., Mascheroni, L., Cattelan, A., Sanantonio, C., Gallino, G. F., Melani, C., Rao, S., Colombo, M. P., Maio, M., Cascinelli, N., and Parmiani, G., Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 44, 197-203, 1997.
116. Veelken, H., Mackensen, A., Lahn, M., Kohler, G., Becker, D., Franke, B., Brennscheidt, U., Kulmburg, P., Rosenthal, F. M., Keller, H., Hasse, J., Schultze-Seeman, W., Farthmann, E. H., Mertelsmann, R., and Lindemann, A., A phase I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 70, 269-277, 1997.
117. Bowman, L. C., Grossmann, M., Rill, D., Brown, M., Zhong, W. Y., Alexander, B., Leimig, T., Coustan-Smith, E., Campana, D., Jenkins, J., Woods, D., and Brenner, M., Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther. 9, 1303-1311, 1998.
118. Suminami, Y., Elder, E. M., Lotze, M. T., and Whiteside, T. L., In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J. Immunother. Emphasis Tumor Immunol. 17, 238-248, 1995.
119. Moller, P., Sun, Y., Dorbic, T., Alijagic, S., Makki, A., Jurgovsky, K., Schroff, M., Henz, B. M., Wittig, B., and Schadendorf, D., Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br. J. Cancer 77, 1907-1916, 1998.
120. Abdel-Wahab, Z., Weltz, C., Hester, D., Pickett, N., Vervaert, C., Barber, J. R., Jolly, D., and Seigler, H. F., A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80, 401-412, 1997.
121. Sun, Y., Jurgovsky, K., Moller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., and Schadendorf, D., Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study. Gene Ther. 5, 481-490, 1998.
122. Jaffee, E. M., Schutte, M., Gossett, J., Morsberger, L. A., Adler, A. J., Thomas, M., Greten, T. F., Hruban, R. H., Yeo, C. J., and Griffin, C. A., Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4, 194-203, 1998.
123. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. J., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M., and Marshall, F. F., Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546, 1997.
124. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K. K., Cosimi, A. B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., and Dranoff, G., Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95, 13141-13146, 1998.
125. Simons, J. W., and Mikhak, B., Ex vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology. Semin. Oncol. 25, 661-676, 1998.
126. Mahvi, D. M., Shi, F.-S., Yang, N.-S., Weber, S., Hank, J., Albertini, M., Schiller, J., Larson, M., Pharo, L., Gan, J., Heisey, D., Warner, T., and Sondel, P. M., Immunization by particle-mediated transfer of the GM-CSF gene into autologous tumor cells in melanoma or sarcoma patients: Report of a Phase I/IB study. Clin. Cancer Res., in press, 1999.